Cancer in Bulgaria

IARC estimates 31,876 new cancer cases and 19,354 cancer deaths in Bulgaria in 2024; the commonest new cancers are colorectum, trachea, bronchus and lung and breast. This page is assembled automatically from OnCo's data: 166 trials with a site there, 2 institutions and 2 people, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

31,876

all cancers

Deaths

19,354

all cancers

Incidence rate

219.9

per 100,000, age-standardised

Mortality rate

117.1

per 100,000, age-standardised

Cumulative risk

23.0%

of a cancer by age 74

Population

6,757,693

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Colorectum	4,371	26.8	Colorectal cancer
Trachea, bronchus and lung	3,884	26.8	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Breast	3,559	53.3	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	3,183	39.8	Prostate cancer
Bladder	1,698	10.5	Bladder & urothelial cancer
Stomach	1,412	8.6	Gastric & gastro-oesophageal junction cancer
Pancreas	1,389	8.6	Pancreatic ductal adenocarcinoma
Corpus uteri	1,197	16.2	Endometrial cancer
Cervix uteri	844	16.0	Cervical cancer
Brain, central nervous system	812	7.0	Glioma & glioblastoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	3,429	21.8	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	2,812	15.2	Colorectal cancer
Breast	1,411	15.5	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Pancreas	1,361	8.1	Pancreatic ductal adenocarcinoma
Prostate	1,285	14.0	Prostate cancer
Stomach	1,079	6.3	Gastric & gastro-oesophageal junction cancer
Bladder	739	3.7	Bladder & urothelial cancer
Liver and intrahepatic bile ducts	711	4.4	Hepatocellular carcinoma
Brain, central nervous system	682	5.3	Glioma & glioblastoma
Ovary	522	6.6	Ovarian cancer

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Bulgaria”, in Eastern Europe (Europe), High HDI, upper middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

166 trials in OnCo · 39 recruiting overall

166 trials

Trial			Lead sponsor
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729	Phase 3	Recruiting	Merck Sharp & Dohme LLC	241	2026-10-07
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521	Phase 3	Recruiting	Relay Therapeutics, Inc.	243	2026-10-05
TeliMET NSCLC-01 NCT04928846	Phase 3	Recruiting	AbbVie	317	2026-10-05
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422	Phase 3	Recruiting	Merck Sharp & Dohme LLC	242	2026-10-02
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma NCT05645107	Phase 3	Recruiting	Grifols Therapeutics LLC	62	2026-09-30
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell NCT07361497	Phase 3	Recruiting	Bristol-Myers Squibb	260	2026-09-30
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P NCT07361510	Phase 3	Recruiting	Bristol-Myers Squibb	284	2026-09-30
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment NCT07472517	Phase 3	Recruiting	Boehringer Ingelheim	245	2026-09-29
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) NCT07099898	Phase 3	Recruiting	GlaxoSmithKline	135	2026-09-28
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) NCT07144280	Phase 3	Recruiting	Pfizer	449	2026-09-28
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277	Phase 3	Recruiting	AstraZeneca	304	2026-09-25
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi NCT05920356	Phase 3	Recruiting	Amgen	420	2026-09-25
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue NCT06989437	Phase 2/3	Recruiting	Pfizer	223	2026-09-25
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. NCT06629779	Phase 3	Recruiting	Pfizer	233	2026-09-25
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC NCT04892173	Phase 3	Recruiting	Johnson & Johnson Enterprise Innovation Inc.	193	2026-09-25
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu NCT06758401	Phase 3	Recruiting	Pfizer	389	2026-09-25
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En NCT07028853	Phase 3	Recruiting	Pfizer	307	2026-09-24
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion NCT07063745	Phase 2/3	Recruiting	Bristol-Myers Squibb	321	2026-09-23
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma NCT06452277	Phase 3	Recruiting	Bayer	279	2026-09-23
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) NCT06875310	Phase 3	Recruiting	Mirati Therapeutics Inc.	351	2026-09-22
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer NCT06712316	Phase 2/3	Recruiting	BioNTech SE	365	2026-09-22
Visugromab in Cachexia International Trial NCT07112196	Phase 2/3	Recruiting	CatalYm GmbH	74	2026-09-22
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) NCT07625644	Phase 3	Recruiting	SystImmune Inc.	62	2026-09-17
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G NCT04613596	Phase 2/3	Recruiting	Mirati Therapeutics Inc.	770	2026-09-16
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer NCT06774131	Phase 3	Recruiting	UroGen Pharma Ltd.	79	2026-09-03
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal NCT06252649	Phase 3	Recruiting	Amgen	291	2026-09-03
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer NCT06380751	Phase 3	Recruiting	AstraZeneca	306	2026-09-02
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B NCT06499285	Phase 3	Recruiting	Takeda	177	2026-08-21
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy NCT05774951	Phase 3	Recruiting	AstraZeneca	709	2026-08-19
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers NCT05882058	Phase 2	Recruiting	Boehringer Ingelheim	59	2026-07-23

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Bulgaria, captured 2026-10-07 to 2026-10-08. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Bulgaria is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

2 institutions

Bulgarian Joint Cancer Network (BJCN)Heart and Brain Hospital, Pleven

2 people

People whose main affiliation in OnCo is an institution or company in Bulgaria.

Assia Konsoulova Toni Vekov

Approvals

Bulgaria is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Bulgaria's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Bulgaria, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Bulgaria's own sources.

A deep dive for Bulgaria is ranked 52 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/bg.json; every country: /api/v1/countries.json.